Review




Structured Review

STEMCELL Technologies Inc stemspantm serum-free expansion medium ii
Stemspantm Serum Free Expansion Medium Ii, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stemspantm+serum-free+expansion+medium+ii/stemspantm+serum+free+expansion+medium++sfem+/pm40378432-47-5-10
Average 90 stars, based on 1 article reviews
stemspantm serum-free expansion medium ii - by Bioz Stars, 2026-09
90/100 stars

Images

Related Articles

Multiple Displacement Amplification:

Article Title: Galectin-1: An important regulator in myeloid differentiation and acute myeloid leukemia as well as a promising prognostic indicator and therapeutic target.
Article Snippet: Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy with a low survival probability and limited therapeutic options.. Although galectin-1 (LGALS1) has been implicated in tumor cell survival and immune evasion in solid tumor, its role in AML is still unclear.. In this study, we found that LGALS1 presents prominent upregulation in AML patients at both mRNA and protein levels compared with the control samples.

Article Title: An engineered model of metastatic colonization of human bone marrow reveals breast cancer cell remodeling of the hematopoietic niche
Article Snippet: After OB maturation, additional BM-MSCs, human umbilical vein ECs (Lonza), and CB-HSPCs (Stem Cell Technologies) were seeded within a fibrin hydrogel on top of the matured endosteal tissues, with or without an additional tumor cell population (i.e., MDA-MB-231 cell line, T47D cell line, or primary BC-derived tumor organoids, among others). eBM tissues colonized with cancer cell lines were maintained with StemSpanTM Serum-Free Expansion Medium II (Stem Cell Technologies) supplemented with 5% heat-inactivated FBS (Corning), 1% P/S (Gibco), selected EGMTM-2 Endothelial Cell Growth Medium-2 BulletKitTM (Lonza) components, and 50 ng/mL each of SCF, TPO, and FLT-3L (PeproTech), for up to 14 d. Experiments conducted for characterization of hematopoietic differentiation trajectory were carried out for 14 d, and experiments with primary tumor organoids were performed for 7 d. For all experiments, subsets of eBM tissues were digested with Collagenase II (Worthington) and Nattokinase (Japan BioSciences) for flow cytometry analysis or RNA sequencing, in addition to a subset of tissues being fixed in 4% paraformaldehyde (Sigma) for histological analysis.

Article Title: Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
Article Snippet: Briefly, CD34+ cells derived from cord blood were cultured in StemSpanTM serum-free expansion medium II (STEMCELL Technologies, Vancouver, British Columbia, Canada) containing StemSpanTM CD34+ expansion supplement (STEMCELL Technologies) in a 5% CO2 atmosphere at 37 C for four days.

Article Title: Identification and interrogation of the gene regulatory network of CEBPA -double mutant acute myeloid leukemia
Article Snippet: C/EBPA N/C -8 cells were cultured at the concentration of 1 × 10 6 cell/mL in StemSpanTM Serum-Free Expansion Medium II (SFEMII) plus 10% StemSpanTM CD34+ Expansion Supplement and 175 nM UM171 (STEMCELL Technologies).

Article Title: Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
Article Snippet: Cells were cultured in StemSpanTM serum-free expansion medium II containing StemSpan erythroid expansion supplement (STEMCELL Technologies) in a 5% CO2 atmosphere at 37 C for five additional days for differentiation into CD36+ cells.

Article Title: Biomarker‑driven phase Ib clinical trial of OPB‑111077 in acute myeloid leukemia
Article Snippet: The Vybrant ® CFDA SE Cell Tracer lit (Thermo Fisher Scientific, Inc.) was used to distinguish between proliferating and non-proliferating cells, and StemSpanTM Serum-Free Expansion Medium II (SFEM II; StemCell Technologies, Inc.) supplemented with StemSpanTM CC100 (StemCell Technologies, Inc.) and autologous plasma was used as the culture medium for proliferation ex vivo assays in both the preliminary preclinical phase, where the approved drug, decitabine, was also used as an anti-proliferative control, and later in the clinical trial.

Article Title: Identification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia.
Article Snippet: Primary cell culture and isolation of hematopoietic stem/ progenitor cells C/EBPAN/C-8 cells were cultured at the concentration of 1 × 106 cell/mL in StemSpanTM Serum-Free Expansion Medium II (SFEMII) plus 10% StemSpanTM CD34+ Expansion Supplement and 175 nM UM171 (STEMCELL Technologies).

Article Title: Patient-derived induced pluripotent stem cells with a MERTK mutation exhibit cell junction abnormalities and aberrant cellular differentiation potential
Article Snippet: PBMCs were cultured in StemSpanTM Serum-Free Expansion Medium II supplemented with StemSpan TM Erythroid Expansion Supplement (STEMCELL Technologies) for 7 d to expand the erythroid cells.

Flow Cytometry:

Article Title: Galectin-1: An important regulator in myeloid differentiation and acute myeloid leukemia as well as a promising prognostic indicator and therapeutic target.
Article Snippet: Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy with a low survival probability and limited therapeutic options.. Although galectin-1 (LGALS1) has been implicated in tumor cell survival and immune evasion in solid tumor, its role in AML is still unclear.. In this study, we found that LGALS1 presents prominent upregulation in AML patients at both mRNA and protein levels compared with the control samples.

Article Title: An engineered model of metastatic colonization of human bone marrow reveals breast cancer cell remodeling of the hematopoietic niche
Article Snippet: After OB maturation, additional BM-MSCs, human umbilical vein ECs (Lonza), and CB-HSPCs (Stem Cell Technologies) were seeded within a fibrin hydrogel on top of the matured endosteal tissues, with or without an additional tumor cell population (i.e., MDA-MB-231 cell line, T47D cell line, or primary BC-derived tumor organoids, among others). eBM tissues colonized with cancer cell lines were maintained with StemSpanTM Serum-Free Expansion Medium II (Stem Cell Technologies) supplemented with 5% heat-inactivated FBS (Corning), 1% P/S (Gibco), selected EGMTM-2 Endothelial Cell Growth Medium-2 BulletKitTM (Lonza) components, and 50 ng/mL each of SCF, TPO, and FLT-3L (PeproTech), for up to 14 d. Experiments conducted for characterization of hematopoietic differentiation trajectory were carried out for 14 d, and experiments with primary tumor organoids were performed for 7 d. For all experiments, subsets of eBM tissues were digested with Collagenase II (Worthington) and Nattokinase (Japan BioSciences) for flow cytometry analysis or RNA sequencing, in addition to a subset of tissues being fixed in 4% paraformaldehyde (Sigma) for histological analysis.

Article Title: Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
Article Snippet: Briefly, CD34+ cells derived from cord blood were cultured in StemSpanTM serum-free expansion medium II (STEMCELL Technologies, Vancouver, British Columbia, Canada) containing StemSpanTM CD34+ expansion supplement (STEMCELL Technologies) in a 5% CO2 atmosphere at 37 C for four days.

Article Title: Identification and interrogation of the gene regulatory network of CEBPA -double mutant acute myeloid leukemia
Article Snippet: C/EBPA N/C -8 cells were cultured at the concentration of 1 × 10 6 cell/mL in StemSpanTM Serum-Free Expansion Medium II (SFEMII) plus 10% StemSpanTM CD34+ Expansion Supplement and 175 nM UM171 (STEMCELL Technologies).

Article Title: Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
Article Snippet: Cells were cultured in StemSpanTM serum-free expansion medium II containing StemSpan erythroid expansion supplement (STEMCELL Technologies) in a 5% CO2 atmosphere at 37 C for five additional days for differentiation into CD36+ cells.

Article Title: Biomarker‑driven phase Ib clinical trial of OPB‑111077 in acute myeloid leukemia
Article Snippet: The Vybrant ® CFDA SE Cell Tracer lit (Thermo Fisher Scientific, Inc.) was used to distinguish between proliferating and non-proliferating cells, and StemSpanTM Serum-Free Expansion Medium II (SFEM II; StemCell Technologies, Inc.) supplemented with StemSpanTM CC100 (StemCell Technologies, Inc.) and autologous plasma was used as the culture medium for proliferation ex vivo assays in both the preliminary preclinical phase, where the approved drug, decitabine, was also used as an anti-proliferative control, and later in the clinical trial.

Article Title: Identification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia.
Article Snippet: Primary cell culture and isolation of hematopoietic stem/ progenitor cells C/EBPAN/C-8 cells were cultured at the concentration of 1 × 106 cell/mL in StemSpanTM Serum-Free Expansion Medium II (SFEMII) plus 10% StemSpanTM CD34+ Expansion Supplement and 175 nM UM171 (STEMCELL Technologies).

Article Title: Patient-derived induced pluripotent stem cells with a MERTK mutation exhibit cell junction abnormalities and aberrant cellular differentiation potential
Article Snippet: PBMCs were cultured in StemSpanTM Serum-Free Expansion Medium II supplemented with StemSpan TM Erythroid Expansion Supplement (STEMCELL Technologies) for 7 d to expand the erythroid cells.

RNA Sequencing:

Article Title: Galectin-1: An important regulator in myeloid differentiation and acute myeloid leukemia as well as a promising prognostic indicator and therapeutic target.
Article Snippet: Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy with a low survival probability and limited therapeutic options.. Although galectin-1 (LGALS1) has been implicated in tumor cell survival and immune evasion in solid tumor, its role in AML is still unclear.. In this study, we found that LGALS1 presents prominent upregulation in AML patients at both mRNA and protein levels compared with the control samples.

Article Title: An engineered model of metastatic colonization of human bone marrow reveals breast cancer cell remodeling of the hematopoietic niche
Article Snippet: After OB maturation, additional BM-MSCs, human umbilical vein ECs (Lonza), and CB-HSPCs (Stem Cell Technologies) were seeded within a fibrin hydrogel on top of the matured endosteal tissues, with or without an additional tumor cell population (i.e., MDA-MB-231 cell line, T47D cell line, or primary BC-derived tumor organoids, among others). eBM tissues colonized with cancer cell lines were maintained with StemSpanTM Serum-Free Expansion Medium II (Stem Cell Technologies) supplemented with 5% heat-inactivated FBS (Corning), 1% P/S (Gibco), selected EGMTM-2 Endothelial Cell Growth Medium-2 BulletKitTM (Lonza) components, and 50 ng/mL each of SCF, TPO, and FLT-3L (PeproTech), for up to 14 d. Experiments conducted for characterization of hematopoietic differentiation trajectory were carried out for 14 d, and experiments with primary tumor organoids were performed for 7 d. For all experiments, subsets of eBM tissues were digested with Collagenase II (Worthington) and Nattokinase (Japan BioSciences) for flow cytometry analysis or RNA sequencing, in addition to a subset of tissues being fixed in 4% paraformaldehyde (Sigma) for histological analysis.

Article Title: Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
Article Snippet: Briefly, CD34+ cells derived from cord blood were cultured in StemSpanTM serum-free expansion medium II (STEMCELL Technologies, Vancouver, British Columbia, Canada) containing StemSpanTM CD34+ expansion supplement (STEMCELL Technologies) in a 5% CO2 atmosphere at 37 C for four days.

Article Title: Identification and interrogation of the gene regulatory network of CEBPA -double mutant acute myeloid leukemia
Article Snippet: C/EBPA N/C -8 cells were cultured at the concentration of 1 × 10 6 cell/mL in StemSpanTM Serum-Free Expansion Medium II (SFEMII) plus 10% StemSpanTM CD34+ Expansion Supplement and 175 nM UM171 (STEMCELL Technologies).

Article Title: Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
Article Snippet: Cells were cultured in StemSpanTM serum-free expansion medium II containing StemSpan erythroid expansion supplement (STEMCELL Technologies) in a 5% CO2 atmosphere at 37 C for five additional days for differentiation into CD36+ cells.

Article Title: Biomarker‑driven phase Ib clinical trial of OPB‑111077 in acute myeloid leukemia
Article Snippet: The Vybrant ® CFDA SE Cell Tracer lit (Thermo Fisher Scientific, Inc.) was used to distinguish between proliferating and non-proliferating cells, and StemSpanTM Serum-Free Expansion Medium II (SFEM II; StemCell Technologies, Inc.) supplemented with StemSpanTM CC100 (StemCell Technologies, Inc.) and autologous plasma was used as the culture medium for proliferation ex vivo assays in both the preliminary preclinical phase, where the approved drug, decitabine, was also used as an anti-proliferative control, and later in the clinical trial.

Article Title: Identification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia.
Article Snippet: Primary cell culture and isolation of hematopoietic stem/ progenitor cells C/EBPAN/C-8 cells were cultured at the concentration of 1 × 106 cell/mL in StemSpanTM Serum-Free Expansion Medium II (SFEMII) plus 10% StemSpanTM CD34+ Expansion Supplement and 175 nM UM171 (STEMCELL Technologies).

Article Title: Patient-derived induced pluripotent stem cells with a MERTK mutation exhibit cell junction abnormalities and aberrant cellular differentiation potential
Article Snippet: PBMCs were cultured in StemSpanTM Serum-Free Expansion Medium II supplemented with StemSpan TM Erythroid Expansion Supplement (STEMCELL Technologies) for 7 d to expand the erythroid cells.

Cell Culture:

Article Title: Galectin-1: An important regulator in myeloid differentiation and acute myeloid leukemia as well as a promising prognostic indicator and therapeutic target.
Article Snippet: Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy with a low survival probability and limited therapeutic options.. Although galectin-1 (LGALS1) has been implicated in tumor cell survival and immune evasion in solid tumor, its role in AML is still unclear.. In this study, we found that LGALS1 presents prominent upregulation in AML patients at both mRNA and protein levels compared with the control samples.

Article Title: An engineered model of metastatic colonization of human bone marrow reveals breast cancer cell remodeling of the hematopoietic niche
Article Snippet: After OB maturation, additional BM-MSCs, human umbilical vein ECs (Lonza), and CB-HSPCs (Stem Cell Technologies) were seeded within a fibrin hydrogel on top of the matured endosteal tissues, with or without an additional tumor cell population (i.e., MDA-MB-231 cell line, T47D cell line, or primary BC-derived tumor organoids, among others). eBM tissues colonized with cancer cell lines were maintained with StemSpanTM Serum-Free Expansion Medium II (Stem Cell Technologies) supplemented with 5% heat-inactivated FBS (Corning), 1% P/S (Gibco), selected EGMTM-2 Endothelial Cell Growth Medium-2 BulletKitTM (Lonza) components, and 50 ng/mL each of SCF, TPO, and FLT-3L (PeproTech), for up to 14 d. Experiments conducted for characterization of hematopoietic differentiation trajectory were carried out for 14 d, and experiments with primary tumor organoids were performed for 7 d. For all experiments, subsets of eBM tissues were digested with Collagenase II (Worthington) and Nattokinase (Japan BioSciences) for flow cytometry analysis or RNA sequencing, in addition to a subset of tissues being fixed in 4% paraformaldehyde (Sigma) for histological analysis.

Article Title: Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
Article Snippet: Briefly, CD34+ cells derived from cord blood were cultured in StemSpanTM serum-free expansion medium II (STEMCELL Technologies, Vancouver, British Columbia, Canada) containing StemSpanTM CD34+ expansion supplement (STEMCELL Technologies) in a 5% CO2 atmosphere at 37 C for four days.

Article Title: Identification and interrogation of the gene regulatory network of CEBPA -double mutant acute myeloid leukemia
Article Snippet: C/EBPA N/C -8 cells were cultured at the concentration of 1 × 10 6 cell/mL in StemSpanTM Serum-Free Expansion Medium II (SFEMII) plus 10% StemSpanTM CD34+ Expansion Supplement and 175 nM UM171 (STEMCELL Technologies).

Article Title: Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
Article Snippet: Cells were cultured in StemSpanTM serum-free expansion medium II containing StemSpan erythroid expansion supplement (STEMCELL Technologies) in a 5% CO2 atmosphere at 37 C for five additional days for differentiation into CD36+ cells.

Article Title: Biomarker‑driven phase Ib clinical trial of OPB‑111077 in acute myeloid leukemia
Article Snippet: The Vybrant ® CFDA SE Cell Tracer lit (Thermo Fisher Scientific, Inc.) was used to distinguish between proliferating and non-proliferating cells, and StemSpanTM Serum-Free Expansion Medium II (SFEM II; StemCell Technologies, Inc.) supplemented with StemSpanTM CC100 (StemCell Technologies, Inc.) and autologous plasma was used as the culture medium for proliferation ex vivo assays in both the preliminary preclinical phase, where the approved drug, decitabine, was also used as an anti-proliferative control, and later in the clinical trial.

Article Title: Identification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia.
Article Snippet: Primary cell culture and isolation of hematopoietic stem/ progenitor cells C/EBPAN/C-8 cells were cultured at the concentration of 1 × 106 cell/mL in StemSpanTM Serum-Free Expansion Medium II (SFEMII) plus 10% StemSpanTM CD34+ Expansion Supplement and 175 nM UM171 (STEMCELL Technologies).

Article Title: Patient-derived induced pluripotent stem cells with a MERTK mutation exhibit cell junction abnormalities and aberrant cellular differentiation potential
Article Snippet: PBMCs were cultured in StemSpanTM Serum-Free Expansion Medium II supplemented with StemSpan TM Erythroid Expansion Supplement (STEMCELL Technologies) for 7 d to expand the erythroid cells.

Isolation:

Article Title: Galectin-1: An important regulator in myeloid differentiation and acute myeloid leukemia as well as a promising prognostic indicator and therapeutic target.
Article Snippet: Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy with a low survival probability and limited therapeutic options.. Although galectin-1 (LGALS1) has been implicated in tumor cell survival and immune evasion in solid tumor, its role in AML is still unclear.. In this study, we found that LGALS1 presents prominent upregulation in AML patients at both mRNA and protein levels compared with the control samples.

Article Title: An engineered model of metastatic colonization of human bone marrow reveals breast cancer cell remodeling of the hematopoietic niche
Article Snippet: After OB maturation, additional BM-MSCs, human umbilical vein ECs (Lonza), and CB-HSPCs (Stem Cell Technologies) were seeded within a fibrin hydrogel on top of the matured endosteal tissues, with or without an additional tumor cell population (i.e., MDA-MB-231 cell line, T47D cell line, or primary BC-derived tumor organoids, among others). eBM tissues colonized with cancer cell lines were maintained with StemSpanTM Serum-Free Expansion Medium II (Stem Cell Technologies) supplemented with 5% heat-inactivated FBS (Corning), 1% P/S (Gibco), selected EGMTM-2 Endothelial Cell Growth Medium-2 BulletKitTM (Lonza) components, and 50 ng/mL each of SCF, TPO, and FLT-3L (PeproTech), for up to 14 d. Experiments conducted for characterization of hematopoietic differentiation trajectory were carried out for 14 d, and experiments with primary tumor organoids were performed for 7 d. For all experiments, subsets of eBM tissues were digested with Collagenase II (Worthington) and Nattokinase (Japan BioSciences) for flow cytometry analysis or RNA sequencing, in addition to a subset of tissues being fixed in 4% paraformaldehyde (Sigma) for histological analysis.

Article Title: Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
Article Snippet: Briefly, CD34+ cells derived from cord blood were cultured in StemSpanTM serum-free expansion medium II (STEMCELL Technologies, Vancouver, British Columbia, Canada) containing StemSpanTM CD34+ expansion supplement (STEMCELL Technologies) in a 5% CO2 atmosphere at 37 C for four days.

Article Title: Identification and interrogation of the gene regulatory network of CEBPA -double mutant acute myeloid leukemia
Article Snippet: C/EBPA N/C -8 cells were cultured at the concentration of 1 × 10 6 cell/mL in StemSpanTM Serum-Free Expansion Medium II (SFEMII) plus 10% StemSpanTM CD34+ Expansion Supplement and 175 nM UM171 (STEMCELL Technologies).

Article Title: Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
Article Snippet: Cells were cultured in StemSpanTM serum-free expansion medium II containing StemSpan erythroid expansion supplement (STEMCELL Technologies) in a 5% CO2 atmosphere at 37 C for five additional days for differentiation into CD36+ cells.

Article Title: Biomarker‑driven phase Ib clinical trial of OPB‑111077 in acute myeloid leukemia
Article Snippet: The Vybrant ® CFDA SE Cell Tracer lit (Thermo Fisher Scientific, Inc.) was used to distinguish between proliferating and non-proliferating cells, and StemSpanTM Serum-Free Expansion Medium II (SFEM II; StemCell Technologies, Inc.) supplemented with StemSpanTM CC100 (StemCell Technologies, Inc.) and autologous plasma was used as the culture medium for proliferation ex vivo assays in both the preliminary preclinical phase, where the approved drug, decitabine, was also used as an anti-proliferative control, and later in the clinical trial.

Article Title: Identification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia.
Article Snippet: Primary cell culture and isolation of hematopoietic stem/ progenitor cells C/EBPAN/C-8 cells were cultured at the concentration of 1 × 106 cell/mL in StemSpanTM Serum-Free Expansion Medium II (SFEMII) plus 10% StemSpanTM CD34+ Expansion Supplement and 175 nM UM171 (STEMCELL Technologies).

Article Title: Patient-derived induced pluripotent stem cells with a MERTK mutation exhibit cell junction abnormalities and aberrant cellular differentiation potential
Article Snippet: PBMCs were cultured in StemSpanTM Serum-Free Expansion Medium II supplemented with StemSpan TM Erythroid Expansion Supplement (STEMCELL Technologies) for 7 d to expand the erythroid cells.

Concentration Assay:

Article Title: Galectin-1: An important regulator in myeloid differentiation and acute myeloid leukemia as well as a promising prognostic indicator and therapeutic target.
Article Snippet: Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy with a low survival probability and limited therapeutic options.. Although galectin-1 (LGALS1) has been implicated in tumor cell survival and immune evasion in solid tumor, its role in AML is still unclear.. In this study, we found that LGALS1 presents prominent upregulation in AML patients at both mRNA and protein levels compared with the control samples.

Article Title: An engineered model of metastatic colonization of human bone marrow reveals breast cancer cell remodeling of the hematopoietic niche
Article Snippet: After OB maturation, additional BM-MSCs, human umbilical vein ECs (Lonza), and CB-HSPCs (Stem Cell Technologies) were seeded within a fibrin hydrogel on top of the matured endosteal tissues, with or without an additional tumor cell population (i.e., MDA-MB-231 cell line, T47D cell line, or primary BC-derived tumor organoids, among others). eBM tissues colonized with cancer cell lines were maintained with StemSpanTM Serum-Free Expansion Medium II (Stem Cell Technologies) supplemented with 5% heat-inactivated FBS (Corning), 1% P/S (Gibco), selected EGMTM-2 Endothelial Cell Growth Medium-2 BulletKitTM (Lonza) components, and 50 ng/mL each of SCF, TPO, and FLT-3L (PeproTech), for up to 14 d. Experiments conducted for characterization of hematopoietic differentiation trajectory were carried out for 14 d, and experiments with primary tumor organoids were performed for 7 d. For all experiments, subsets of eBM tissues were digested with Collagenase II (Worthington) and Nattokinase (Japan BioSciences) for flow cytometry analysis or RNA sequencing, in addition to a subset of tissues being fixed in 4% paraformaldehyde (Sigma) for histological analysis.

Article Title: Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
Article Snippet: Briefly, CD34+ cells derived from cord blood were cultured in StemSpanTM serum-free expansion medium II (STEMCELL Technologies, Vancouver, British Columbia, Canada) containing StemSpanTM CD34+ expansion supplement (STEMCELL Technologies) in a 5% CO2 atmosphere at 37 C for four days.

Article Title: Identification and interrogation of the gene regulatory network of CEBPA -double mutant acute myeloid leukemia
Article Snippet: C/EBPA N/C -8 cells were cultured at the concentration of 1 × 10 6 cell/mL in StemSpanTM Serum-Free Expansion Medium II (SFEMII) plus 10% StemSpanTM CD34+ Expansion Supplement and 175 nM UM171 (STEMCELL Technologies).

Article Title: Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
Article Snippet: Cells were cultured in StemSpanTM serum-free expansion medium II containing StemSpan erythroid expansion supplement (STEMCELL Technologies) in a 5% CO2 atmosphere at 37 C for five additional days for differentiation into CD36+ cells.

Article Title: Biomarker‑driven phase Ib clinical trial of OPB‑111077 in acute myeloid leukemia
Article Snippet: The Vybrant ® CFDA SE Cell Tracer lit (Thermo Fisher Scientific, Inc.) was used to distinguish between proliferating and non-proliferating cells, and StemSpanTM Serum-Free Expansion Medium II (SFEM II; StemCell Technologies, Inc.) supplemented with StemSpanTM CC100 (StemCell Technologies, Inc.) and autologous plasma was used as the culture medium for proliferation ex vivo assays in both the preliminary preclinical phase, where the approved drug, decitabine, was also used as an anti-proliferative control, and later in the clinical trial.

Article Title: Identification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia.
Article Snippet: Primary cell culture and isolation of hematopoietic stem/ progenitor cells C/EBPAN/C-8 cells were cultured at the concentration of 1 × 106 cell/mL in StemSpanTM Serum-Free Expansion Medium II (SFEMII) plus 10% StemSpanTM CD34+ Expansion Supplement and 175 nM UM171 (STEMCELL Technologies).

Article Title: Patient-derived induced pluripotent stem cells with a MERTK mutation exhibit cell junction abnormalities and aberrant cellular differentiation potential
Article Snippet: PBMCs were cultured in StemSpanTM Serum-Free Expansion Medium II supplemented with StemSpan TM Erythroid Expansion Supplement (STEMCELL Technologies) for 7 d to expand the erythroid cells.

Derivative Assay:

Article Title: Galectin-1: An important regulator in myeloid differentiation and acute myeloid leukemia as well as a promising prognostic indicator and therapeutic target.
Article Snippet: Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy with a low survival probability and limited therapeutic options.. Although galectin-1 (LGALS1) has been implicated in tumor cell survival and immune evasion in solid tumor, its role in AML is still unclear.. In this study, we found that LGALS1 presents prominent upregulation in AML patients at both mRNA and protein levels compared with the control samples.

Article Title: An engineered model of metastatic colonization of human bone marrow reveals breast cancer cell remodeling of the hematopoietic niche
Article Snippet: After OB maturation, additional BM-MSCs, human umbilical vein ECs (Lonza), and CB-HSPCs (Stem Cell Technologies) were seeded within a fibrin hydrogel on top of the matured endosteal tissues, with or without an additional tumor cell population (i.e., MDA-MB-231 cell line, T47D cell line, or primary BC-derived tumor organoids, among others). eBM tissues colonized with cancer cell lines were maintained with StemSpanTM Serum-Free Expansion Medium II (Stem Cell Technologies) supplemented with 5% heat-inactivated FBS (Corning), 1% P/S (Gibco), selected EGMTM-2 Endothelial Cell Growth Medium-2 BulletKitTM (Lonza) components, and 50 ng/mL each of SCF, TPO, and FLT-3L (PeproTech), for up to 14 d. Experiments conducted for characterization of hematopoietic differentiation trajectory were carried out for 14 d, and experiments with primary tumor organoids were performed for 7 d. For all experiments, subsets of eBM tissues were digested with Collagenase II (Worthington) and Nattokinase (Japan BioSciences) for flow cytometry analysis or RNA sequencing, in addition to a subset of tissues being fixed in 4% paraformaldehyde (Sigma) for histological analysis.

Article Title: Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
Article Snippet: Briefly, CD34+ cells derived from cord blood were cultured in StemSpanTM serum-free expansion medium II (STEMCELL Technologies, Vancouver, British Columbia, Canada) containing StemSpanTM CD34+ expansion supplement (STEMCELL Technologies) in a 5% CO2 atmosphere at 37 C for four days.

Article Title: Identification and interrogation of the gene regulatory network of CEBPA -double mutant acute myeloid leukemia
Article Snippet: C/EBPA N/C -8 cells were cultured at the concentration of 1 × 10 6 cell/mL in StemSpanTM Serum-Free Expansion Medium II (SFEMII) plus 10% StemSpanTM CD34+ Expansion Supplement and 175 nM UM171 (STEMCELL Technologies).

Article Title: Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
Article Snippet: Cells were cultured in StemSpanTM serum-free expansion medium II containing StemSpan erythroid expansion supplement (STEMCELL Technologies) in a 5% CO2 atmosphere at 37 C for five additional days for differentiation into CD36+ cells.

Article Title: Biomarker‑driven phase Ib clinical trial of OPB‑111077 in acute myeloid leukemia
Article Snippet: The Vybrant ® CFDA SE Cell Tracer lit (Thermo Fisher Scientific, Inc.) was used to distinguish between proliferating and non-proliferating cells, and StemSpanTM Serum-Free Expansion Medium II (SFEM II; StemCell Technologies, Inc.) supplemented with StemSpanTM CC100 (StemCell Technologies, Inc.) and autologous plasma was used as the culture medium for proliferation ex vivo assays in both the preliminary preclinical phase, where the approved drug, decitabine, was also used as an anti-proliferative control, and later in the clinical trial.

Article Title: Identification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia.
Article Snippet: Primary cell culture and isolation of hematopoietic stem/ progenitor cells C/EBPAN/C-8 cells were cultured at the concentration of 1 × 106 cell/mL in StemSpanTM Serum-Free Expansion Medium II (SFEMII) plus 10% StemSpanTM CD34+ Expansion Supplement and 175 nM UM171 (STEMCELL Technologies).

Article Title: Patient-derived induced pluripotent stem cells with a MERTK mutation exhibit cell junction abnormalities and aberrant cellular differentiation potential
Article Snippet: PBMCs were cultured in StemSpanTM Serum-Free Expansion Medium II supplemented with StemSpan TM Erythroid Expansion Supplement (STEMCELL Technologies) for 7 d to expand the erythroid cells.

Clinical Proteomics:

Article Title: Galectin-1: An important regulator in myeloid differentiation and acute myeloid leukemia as well as a promising prognostic indicator and therapeutic target.
Article Snippet: Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy with a low survival probability and limited therapeutic options.. Although galectin-1 (LGALS1) has been implicated in tumor cell survival and immune evasion in solid tumor, its role in AML is still unclear.. In this study, we found that LGALS1 presents prominent upregulation in AML patients at both mRNA and protein levels compared with the control samples.

Article Title: An engineered model of metastatic colonization of human bone marrow reveals breast cancer cell remodeling of the hematopoietic niche
Article Snippet: After OB maturation, additional BM-MSCs, human umbilical vein ECs (Lonza), and CB-HSPCs (Stem Cell Technologies) were seeded within a fibrin hydrogel on top of the matured endosteal tissues, with or without an additional tumor cell population (i.e., MDA-MB-231 cell line, T47D cell line, or primary BC-derived tumor organoids, among others). eBM tissues colonized with cancer cell lines were maintained with StemSpanTM Serum-Free Expansion Medium II (Stem Cell Technologies) supplemented with 5% heat-inactivated FBS (Corning), 1% P/S (Gibco), selected EGMTM-2 Endothelial Cell Growth Medium-2 BulletKitTM (Lonza) components, and 50 ng/mL each of SCF, TPO, and FLT-3L (PeproTech), for up to 14 d. Experiments conducted for characterization of hematopoietic differentiation trajectory were carried out for 14 d, and experiments with primary tumor organoids were performed for 7 d. For all experiments, subsets of eBM tissues were digested with Collagenase II (Worthington) and Nattokinase (Japan BioSciences) for flow cytometry analysis or RNA sequencing, in addition to a subset of tissues being fixed in 4% paraformaldehyde (Sigma) for histological analysis.

Article Title: Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
Article Snippet: Briefly, CD34+ cells derived from cord blood were cultured in StemSpanTM serum-free expansion medium II (STEMCELL Technologies, Vancouver, British Columbia, Canada) containing StemSpanTM CD34+ expansion supplement (STEMCELL Technologies) in a 5% CO2 atmosphere at 37 C for four days.

Article Title: Identification and interrogation of the gene regulatory network of CEBPA -double mutant acute myeloid leukemia
Article Snippet: C/EBPA N/C -8 cells were cultured at the concentration of 1 × 10 6 cell/mL in StemSpanTM Serum-Free Expansion Medium II (SFEMII) plus 10% StemSpanTM CD34+ Expansion Supplement and 175 nM UM171 (STEMCELL Technologies).

Article Title: Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
Article Snippet: Cells were cultured in StemSpanTM serum-free expansion medium II containing StemSpan erythroid expansion supplement (STEMCELL Technologies) in a 5% CO2 atmosphere at 37 C for five additional days for differentiation into CD36+ cells.

Article Title: Biomarker‑driven phase Ib clinical trial of OPB‑111077 in acute myeloid leukemia
Article Snippet: The Vybrant ® CFDA SE Cell Tracer lit (Thermo Fisher Scientific, Inc.) was used to distinguish between proliferating and non-proliferating cells, and StemSpanTM Serum-Free Expansion Medium II (SFEM II; StemCell Technologies, Inc.) supplemented with StemSpanTM CC100 (StemCell Technologies, Inc.) and autologous plasma was used as the culture medium for proliferation ex vivo assays in both the preliminary preclinical phase, where the approved drug, decitabine, was also used as an anti-proliferative control, and later in the clinical trial.

Article Title: Identification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia.
Article Snippet: Primary cell culture and isolation of hematopoietic stem/ progenitor cells C/EBPAN/C-8 cells were cultured at the concentration of 1 × 106 cell/mL in StemSpanTM Serum-Free Expansion Medium II (SFEMII) plus 10% StemSpanTM CD34+ Expansion Supplement and 175 nM UM171 (STEMCELL Technologies).

Article Title: Patient-derived induced pluripotent stem cells with a MERTK mutation exhibit cell junction abnormalities and aberrant cellular differentiation potential
Article Snippet: PBMCs were cultured in StemSpanTM Serum-Free Expansion Medium II supplemented with StemSpan TM Erythroid Expansion Supplement (STEMCELL Technologies) for 7 d to expand the erythroid cells.

Ex Vivo:

Article Title: Galectin-1: An important regulator in myeloid differentiation and acute myeloid leukemia as well as a promising prognostic indicator and therapeutic target.
Article Snippet: Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy with a low survival probability and limited therapeutic options.. Although galectin-1 (LGALS1) has been implicated in tumor cell survival and immune evasion in solid tumor, its role in AML is still unclear.. In this study, we found that LGALS1 presents prominent upregulation in AML patients at both mRNA and protein levels compared with the control samples.

Article Title: An engineered model of metastatic colonization of human bone marrow reveals breast cancer cell remodeling of the hematopoietic niche
Article Snippet: After OB maturation, additional BM-MSCs, human umbilical vein ECs (Lonza), and CB-HSPCs (Stem Cell Technologies) were seeded within a fibrin hydrogel on top of the matured endosteal tissues, with or without an additional tumor cell population (i.e., MDA-MB-231 cell line, T47D cell line, or primary BC-derived tumor organoids, among others). eBM tissues colonized with cancer cell lines were maintained with StemSpanTM Serum-Free Expansion Medium II (Stem Cell Technologies) supplemented with 5% heat-inactivated FBS (Corning), 1% P/S (Gibco), selected EGMTM-2 Endothelial Cell Growth Medium-2 BulletKitTM (Lonza) components, and 50 ng/mL each of SCF, TPO, and FLT-3L (PeproTech), for up to 14 d. Experiments conducted for characterization of hematopoietic differentiation trajectory were carried out for 14 d, and experiments with primary tumor organoids were performed for 7 d. For all experiments, subsets of eBM tissues were digested with Collagenase II (Worthington) and Nattokinase (Japan BioSciences) for flow cytometry analysis or RNA sequencing, in addition to a subset of tissues being fixed in 4% paraformaldehyde (Sigma) for histological analysis.

Article Title: Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
Article Snippet: Briefly, CD34+ cells derived from cord blood were cultured in StemSpanTM serum-free expansion medium II (STEMCELL Technologies, Vancouver, British Columbia, Canada) containing StemSpanTM CD34+ expansion supplement (STEMCELL Technologies) in a 5% CO2 atmosphere at 37 C for four days.

Article Title: Identification and interrogation of the gene regulatory network of CEBPA -double mutant acute myeloid leukemia
Article Snippet: C/EBPA N/C -8 cells were cultured at the concentration of 1 × 10 6 cell/mL in StemSpanTM Serum-Free Expansion Medium II (SFEMII) plus 10% StemSpanTM CD34+ Expansion Supplement and 175 nM UM171 (STEMCELL Technologies).

Article Title: Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
Article Snippet: Cells were cultured in StemSpanTM serum-free expansion medium II containing StemSpan erythroid expansion supplement (STEMCELL Technologies) in a 5% CO2 atmosphere at 37 C for five additional days for differentiation into CD36+ cells.

Article Title: Biomarker‑driven phase Ib clinical trial of OPB‑111077 in acute myeloid leukemia
Article Snippet: The Vybrant ® CFDA SE Cell Tracer lit (Thermo Fisher Scientific, Inc.) was used to distinguish between proliferating and non-proliferating cells, and StemSpanTM Serum-Free Expansion Medium II (SFEM II; StemCell Technologies, Inc.) supplemented with StemSpanTM CC100 (StemCell Technologies, Inc.) and autologous plasma was used as the culture medium for proliferation ex vivo assays in both the preliminary preclinical phase, where the approved drug, decitabine, was also used as an anti-proliferative control, and later in the clinical trial.

Article Title: Identification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia.
Article Snippet: Primary cell culture and isolation of hematopoietic stem/ progenitor cells C/EBPAN/C-8 cells were cultured at the concentration of 1 × 106 cell/mL in StemSpanTM Serum-Free Expansion Medium II (SFEMII) plus 10% StemSpanTM CD34+ Expansion Supplement and 175 nM UM171 (STEMCELL Technologies).

Article Title: Patient-derived induced pluripotent stem cells with a MERTK mutation exhibit cell junction abnormalities and aberrant cellular differentiation potential
Article Snippet: PBMCs were cultured in StemSpanTM Serum-Free Expansion Medium II supplemented with StemSpan TM Erythroid Expansion Supplement (STEMCELL Technologies) for 7 d to expand the erythroid cells.

Control:

Article Title: Galectin-1: An important regulator in myeloid differentiation and acute myeloid leukemia as well as a promising prognostic indicator and therapeutic target.
Article Snippet: Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy with a low survival probability and limited therapeutic options.. Although galectin-1 (LGALS1) has been implicated in tumor cell survival and immune evasion in solid tumor, its role in AML is still unclear.. In this study, we found that LGALS1 presents prominent upregulation in AML patients at both mRNA and protein levels compared with the control samples.

Article Title: An engineered model of metastatic colonization of human bone marrow reveals breast cancer cell remodeling of the hematopoietic niche
Article Snippet: After OB maturation, additional BM-MSCs, human umbilical vein ECs (Lonza), and CB-HSPCs (Stem Cell Technologies) were seeded within a fibrin hydrogel on top of the matured endosteal tissues, with or without an additional tumor cell population (i.e., MDA-MB-231 cell line, T47D cell line, or primary BC-derived tumor organoids, among others). eBM tissues colonized with cancer cell lines were maintained with StemSpanTM Serum-Free Expansion Medium II (Stem Cell Technologies) supplemented with 5% heat-inactivated FBS (Corning), 1% P/S (Gibco), selected EGMTM-2 Endothelial Cell Growth Medium-2 BulletKitTM (Lonza) components, and 50 ng/mL each of SCF, TPO, and FLT-3L (PeproTech), for up to 14 d. Experiments conducted for characterization of hematopoietic differentiation trajectory were carried out for 14 d, and experiments with primary tumor organoids were performed for 7 d. For all experiments, subsets of eBM tissues were digested with Collagenase II (Worthington) and Nattokinase (Japan BioSciences) for flow cytometry analysis or RNA sequencing, in addition to a subset of tissues being fixed in 4% paraformaldehyde (Sigma) for histological analysis.

Article Title: Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
Article Snippet: Briefly, CD34+ cells derived from cord blood were cultured in StemSpanTM serum-free expansion medium II (STEMCELL Technologies, Vancouver, British Columbia, Canada) containing StemSpanTM CD34+ expansion supplement (STEMCELL Technologies) in a 5% CO2 atmosphere at 37 C for four days.

Article Title: Identification and interrogation of the gene regulatory network of CEBPA -double mutant acute myeloid leukemia
Article Snippet: C/EBPA N/C -8 cells were cultured at the concentration of 1 × 10 6 cell/mL in StemSpanTM Serum-Free Expansion Medium II (SFEMII) plus 10% StemSpanTM CD34+ Expansion Supplement and 175 nM UM171 (STEMCELL Technologies).

Article Title: Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
Article Snippet: Cells were cultured in StemSpanTM serum-free expansion medium II containing StemSpan erythroid expansion supplement (STEMCELL Technologies) in a 5% CO2 atmosphere at 37 C for five additional days for differentiation into CD36+ cells.

Article Title: Biomarker‑driven phase Ib clinical trial of OPB‑111077 in acute myeloid leukemia
Article Snippet: The Vybrant ® CFDA SE Cell Tracer lit (Thermo Fisher Scientific, Inc.) was used to distinguish between proliferating and non-proliferating cells, and StemSpanTM Serum-Free Expansion Medium II (SFEM II; StemCell Technologies, Inc.) supplemented with StemSpanTM CC100 (StemCell Technologies, Inc.) and autologous plasma was used as the culture medium for proliferation ex vivo assays in both the preliminary preclinical phase, where the approved drug, decitabine, was also used as an anti-proliferative control, and later in the clinical trial.

Article Title: Identification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia.
Article Snippet: Primary cell culture and isolation of hematopoietic stem/ progenitor cells C/EBPAN/C-8 cells were cultured at the concentration of 1 × 106 cell/mL in StemSpanTM Serum-Free Expansion Medium II (SFEMII) plus 10% StemSpanTM CD34+ Expansion Supplement and 175 nM UM171 (STEMCELL Technologies).

Article Title: Patient-derived induced pluripotent stem cells with a MERTK mutation exhibit cell junction abnormalities and aberrant cellular differentiation potential
Article Snippet: PBMCs were cultured in StemSpanTM Serum-Free Expansion Medium II supplemented with StemSpan TM Erythroid Expansion Supplement (STEMCELL Technologies) for 7 d to expand the erythroid cells.



Similar Products

90
STEMCELL Technologies Inc stemspantm serum-free expansion medium ii
Stemspantm Serum Free Expansion Medium Ii, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stemspantm+serum-free+expansion+medium+ii/stemspantm+serum+free+expansion+medium++sfem+/pm40378432-47-5-10
Average 90 stars, based on 1 article reviews
stemspantm serum-free expansion medium ii - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc stemspantm serum-free expansion medium ii (sfem ii) (stemcell #09605)
Stemspantm Serum Free Expansion Medium Ii (Sfem Ii) (Stemcell #09605), supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stemspantm+serum-free+expansion+medium+ii/stemspantm+serum+free+expansion+medium++sfem+/bio_rxiv__2024__12__20__629809-161-6-13
Average 90 stars, based on 1 article reviews
stemspantm serum-free expansion medium ii (sfem ii) (stemcell #09605) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc stemspantm serum-free expansion medium (sfem) ii
Stemspantm Serum Free Expansion Medium (Sfem) Ii, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stemspantm+serum-free+expansion+medium+ii/stemspantm+serum+free+expansion+medium++sfem+/bio_rxiv__2024__02__05__578960-181-11-18
Average 90 stars, based on 1 article reviews
stemspantm serum-free expansion medium (sfem) ii - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc stemspantm serum-free expansion medium ii (sfem ii)

Stemspantm Serum Free Expansion Medium Ii (Sfem Ii), supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stemspantm+serum-free+expansion+medium+ii/stemspantm+serum+free+expansion+medium++sfem+/pmc10428076-164-0-8
Average 90 stars, based on 1 article reviews
stemspantm serum-free expansion medium ii (sfem ii) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Journal: Cell reports

Article Title: Activation of GPR44 decreases severity of myeloid leukemia via specific targeting of leukemia initiating stem cells

doi: 10.1016/j.celrep.2023.112794

Figure Lengend Snippet:

Article Snippet: StemSpanTM serum-free expansion medium II (SFEM II) , Stem Cell Technologies , Cat# 09655.

Techniques: Virus, Recombinant, Enzyme-linked Immunosorbent Assay, Binding Assay, Staining, Modification, Saline, Concentration Assay, Over Expression, Protein Extraction, Membrane, SYBR Green Assay, Bicinchoninic Acid Protein Assay, Protease Inhibitor, CCK-8 Assay, Reverse Transcription, Selection, Plasmid Preparation, Knock-Out, Software, Real-time Polymerase Chain Reaction, Flow Cytometry